A Possible Novel Anti-Inflammatory Mechanism for the Pharmacological Prolyl Hydroxylase Inhibitor 3,4-Dihydroxybenzoate: Implications for Use as a Therapeutic for Parkinson’s Disease

Figure 6

BV2 cells were stimulated with LPS (100 ng/mL) ± DHB (100 μM) for 24 h. CM from control (BV2-CM), DHB treated (DHB-CM), LPS-treated (LPS-CM), and LPS/DHB treated (50 & 100 μM; LPD50-CM, LDP100-CM) BV2 cells was added to dopaminergic N27 cells plated in 96 well plates. After 48 h, N27 cell viability was assessed via the MTT assay. Data is expressed as mean ± SD, 𝑛=4. *𝑃<0.01, compared with control-CM group, **𝑃<0.01, compared with LPS-CM group.